Across TCGA pan-cancer cohorts, XKR9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated XKR9 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher XKR9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated XKR9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where XKR9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	48	view →
UCEC	DFS	Median	All	0.950	0.622	.023	4	view →
SKCM	DFS	Median	III,IV	0.202	0.653	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: XKR9 tumor-vs-normal RNA expression · all XKR9 data types